• Explore /
  • Poster
  • / A phase Ib, multicenter, open-label study to assess the safety, tolerability, and preliminary efficacy of sintilimab plus IBI310 (anti-CTLA4 mAb) in patients with advanced hepatocellular carcinoma.

A phase Ib, multicenter, open-label study to assess the safety, tolerability, and preliminary efficacy of sintilimab plus IBI310 (anti-CTLA4 mAb) in patients with advanced hepatocellular carcinoma.

Abstract Poster

Authors

null

Jian Zhou

Department of Liver Surgery and Transplantation, Zhongshan Hospital and Liver Cancer Institute, Fudan University, Shanghai, China

Jian Zhou , Ying-Hong Shi , Baorui Liu , Wei-Dong Jia , Shanzhi Gu , Yanru Qin , Ying Liu , Zhengxiang Han

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04401813

DOI

10.1200/JCO.2022.40.4_suppl.421

Abstract #

421

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ming Liu

First Author: Shuiling Jin

First Author: Wen Zhang

First Author: Timothy J. Brown